High-intensity focused ultrasound offers noninvasive treatment for cancer patients

High-intensity focused ultrasound (HIFU) may potentially replace drug treatment for pain in cancer patients when combined with surgery, radiation therapy or chemotherapy, according to new research published online in the March-April 2018 issue of Radiographics.  

Cancer related pain may directly stem from tumors, injury to nociceptors or result from surgery or radiation therapy and is commonly treated with prescribed opioid analgesics. The noninvasive technique of HIFU however, which is approved for uterine fibroids, bone metastases, essential tremors and encouraged to treat pancreatic cancers, may be more effective than drugs and spare patients serious side effects and toxicity, according to researchers.  

At the forefront of HIPU treatment is precision: MRI technology localizes high-intensity ultrasound waves on a targeted region of the body without damaging surrounding tissues or organs. 

Noninvasive in nature and able to be safely repeated and combined with chemotherapy or radiation therapy, HIPU alleviates cancer related pain through tissue denervation, tumor mass reduction and neuromodulation, the researchers wrote, ultimately offering a multimodality approach to treating malignant diseases.   

"Currently, MRI guided HIFU is recommended as a second-line treatment after unsuccessful radiation therapy for palliation of pain related to non-spinal and non-skull bone metastases," wrote lead author Susan Dababou, MD, from the department of radiological sciences at Sapienza University of Rome. "It can be used as a first-line treatment when radiation therapy is contraindicated, or the patient refuses to receive it." 

The main benefits of HIFU treating cancer related pain includes decreasing painful stimuli, locally controlling tumors, enhancing local drug delivery and stimulating the host antineoplastic immune response, among others, Dababou and colleagues wrote. Further research is suggested to investigate whether patients will benefit from HIFU in the long term and could be a primary, secondary or complementary treatment for cancer pain management.  

""

A recent graduate from Dominican University (IL) with a bachelor’s in journalism, Melissa joined TriMed’s Chicago team in 2017 covering all aspects of health imaging. She’s a fan of singing and playing guitar, elephants, a good cup of tea, and her golden retriever Cooper.

Around the web

CCTA is being utilized more and more for the diagnosis and management of suspected coronary artery disease. An international group of specialists shared their perspective on this ongoing trend.

The new technology shows early potential to make a significant impact on imaging workflows and patient care. 

Richard Heller III, MD, RSNA board member and senior VP of policy at Radiology Partners, offers an overview of policies in Congress that are directly impacting imaging.